ArticlePharmacology research & perspectives2025
Molecular Docking, Dynamics, and Preclinical Studies Reveal Morin Hydrate as a Potent PPARγ and Nrf2 Agonist That Mitigates Colon Inflammation.
Article in Pharmacology research & perspectives, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Morin and Morin Semicarbazone Combined with Fucoxanthin Have Potential Anti-Inflammaging Effects Through Modulation of Nrf2/HO-1 System in UVB-Exposed HaCaT Keratinocytes.Antioxidants (Basel, Switzerland) · 2026Article
- Therapeutic Agents Targeting the Nrf2 Signaling Pathway to Combat Oxidative Stress and Intestinal Inflammation in Veterinary and Translational Medicine.Veterinary sciences · 2025Review
- Molecular Docking, Dynamics, and Preclinical Studies Reveal Morin Hydrate as a Potent PPARγ and Nrf2 Agonist That Mitigates Colon Inflammation.Pharmacology research & perspectives · 2025Article
- Next-generation non-animal models for inflammatory bowel disease:NAM journal · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Peroxisome proliferator-activated receptors (PPARs), functioning as nuclear receptors, regulate the expression of genes associated with inflammation, lipid metabolism, and glucose metabolism. The primary isotypes of PPARs are PPARα, PPARβ, and PPARγ. PPARγ is mostly expressed in adipose tissue and the colon. The activation of PPARγ modulates signaling pathways associated with metabolism and inflammation. Inflammatory bowel diseases (IBDs) include Crohn's disease and ulcerative colitis (UC). Ulcerative colitis is predominantly localized to the colon. Considering PPARγ's expression profile and its role in alleviating inflammation, there exists an opportunity to explore pharmaceutical targeting in the colon to diminish inflammation. We conducted molecular docking and dynamics investigations utilizing Morin hydrate (MH), a flavonoid derived from the Moraceae family, with the cocrystal structure of PPARγ and Nrf2. They demonstrated a consistent interaction. Consequently, we conducted comprehensive preclinical studies of these interactions utilizing both in vivo and in vitro models of colon inflammation. Our findings showed that MH reduced the disease activity index, colon length shortening, and myeloperoxidase enzyme activity in mice treated with dextran sodium sulfate (DSS). MH also safeguarded colon histology by reducing proinflammatory cytokines. MH induced Nrf2 nuclear translocation, enhanced antioxidant response, and elevated Nrf2 promoter activity. MH selectively enhanced PPARγ protein expression while leaving other PPAR isotypes unaffected. HT-29 cells, treated with tumor necrosis factor-alpha (TNFα) as an in vitro model of colon inflammation, exhibited a reduction in proinflammatory chemokines with exposure to MH. MH also enhanced PPARγ promoter activity. These findings demonstrate that MH is a potent agonist of Nrf2 and PPARγ, resulting in reduced colon inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.